Feb 16, 2021
Pulmatrix Announces Closing of $40 Million Registered Direct Offering
Nov 12, 2020
Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates
Oct 21, 2020
Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud
Sep 30, 2020
Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles
Sep 29, 2020
Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore
Sep 22, 2020
Pulmatrix Reports Progress on Product Pipeline
Jul 08, 2020
Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles
May 27, 2020
Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually
May 14, 2020
Pulmatrix Reports Q1 2020 Results
Apr 16, 2020
Pulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Apr 16, 2020
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19
Mar 26, 2020
Pulmatrix Reports 2019 Financial Results and Provides Business Update
Jan 30, 2020
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
Jan 16, 2020
Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jan 06, 2020
Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies
Jan 02, 2020
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
Nov 04, 2019
Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors
Nov 01, 2019
Pulmatrix Reports Q3 2019 Results
Aug 19, 2019
Pulmatrix Receives US Patent Covering iSPERSE(TM) Formulations for Pulmazole Program
Aug 05, 2019
Pulmatrix Reports Q2 2019 Results